NRIX

NEUTRALProduct

Nurix Therapeutics, Inc.

2026-08-19

Price

$27.79

+3.19%

This is the 2026-08-19 snapshot — the signals and analysis for NRIX as of this single trading day.

View full NRIX research hub →

Score6.0Priority

Signals6/8 DNA1/13 Act · 2/4 Risk

SentimentNEUTRALScore: 8

Volume1.9xvs 20d avg

Analysis

Nurix Therapeutics is experiencing high-conviction price discovery, driven by major structural pipeline validations and a highly supportive macro backdrop. The stock's SURGE and PERFECT_STACK signals, accompanied by urgent 1.9x average volume, confirm aggressive institutional accumulation as it breaks out to new 52-week highs. This momentum is heavily amplified by the current RISK_ON (RATES) regime, where pulling-back Treasury yields and ultra-tight credit spreads create the ideal environment for high-beta, clinical-stage biotechs to out-trend the broader market.

Fired Signals

SURGEALPHA MALESTEADY CLIMBGOLDEN CROSSMARKET LEADERPERFECT STACKINSIDE OUTWEAK FINISHEXTENSION

Key Takeaways

Actionable Thesis: NRIX is in a confirmed breakout fueled by its $2.3B Roche collaboration and recent $10M Sanofi milestone, making it a high-conviction momentum vehicle in a rate-friendly tape.
Key Risk: Despite the strong technical stack, as a clinical-stage biotech, NRIX remains highly vulnerable to sudden clinical trial setbacks or abrupt reversals in the macro yield environment.
What to Watch: Monitor price action around the new $27.79 high for continuation, using the $22.71 20-day closing low as a strict trailing risk-management level.

← Back to 2026-08-19 View Full NRIX History →Yahoo Finance &nearr;